Aldeyra Therapeutics (ALDX) Change in Acquisitions & Divestments (2016 - 2025)

Aldeyra Therapeutics' Change in Acquisitions & Divestments history runs 9 years deep, the most recent figure standing at $16.0 million for Q4 2025.

• Quarterly Change in Acquisitions & Divestments fell 20.0% year-over-year to $16.0 million in Q4 2025, while the trailing twelve-month figure through Mar 2026 was $65.0 million (down 13.33% YoY) and the FY2025 annual result came in at $88.0 million, up 69.23% from the prior year.
• Change in Acquisitions & Divestments was $16.0 million for Q4 2025 at Aldeyra Therapeutics, down from $25.0 million in the prior quarter.
• Across five years, Change in Acquisitions & Divestments topped out at $30.0 million in Q1 2023 and bottomed at $12.0 million in Q2 2022.
• A 4-year average of $21.2 million and a median of $23.0 million in 2025 frame the typical range for Change in Acquisitions & Divestments.
• Peak annual rise in Change in Acquisitions & Divestments reached 100.0% in 2025, while the deepest fall reached 20.0% in 2025.
• Aldeyra Therapeutics' Change in Acquisitions & Divestments stood at $27.0 million in 2022, then advanced by 11.11% to $30.0 million in 2023, then slumped by 33.33% to $20.0 million in 2024, then declined by 20.0% to $16.0 million in 2025.
• Business Quant data shows ALDX's Change in Acquisitions & Divestments at $16.0 million in Q4 2025, $25.0 million in Q3 2025, and $24.0 million in Q2 2025.